跳至主要内容
临床试验/NCT04088019
NCT04088019招募中不适用

Proportion of Clinical Improvement and Score Comparison of Type 1 Interferon, Transcriptomic Analysis in Idiopathic Uveitis Patients With IGRA Positive Before and After Anti-Tuberculosis Drugs Treatment: Cohort Prospective Study

Fakultas Kedokteran Universitas Indonesia1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年10月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
50
试验地点
1
主要终点
Proportion of clinical improvement

研究概览

简要总结

The aim of this study is to determine the proportion of clinical improvement, the score changing of type 1 interferon selected gene expression, and analysis of transcriptomics profiling in patients with idiopathic uveitis positive IGRA before and after receiving Anti-Tuberculosis Therapy (ATT).

Hopefully, by conducting this research, we are able to provide valid data that demonstrate the advantages/disadvantages usage of Anti-Tuberculosis Therapy in patients with idiopathic uveitis IGRA positive that correlate with type I IFN. This research is a part of our efforts in discovering bio-marker candidates of idiopathic uveitis IGRA positive clinical patients who will benefit from the ATT administration.

详细描述

Diagnostic of Idiopathic Uveitis IGRA Positive patients were still unclear. This situation happens because it is still can't be explained if the uveitis from the patients was caused by mycobacterium tuberculosis or not which leads to doubtfulness for Anti-Tuberculosis Treatment (ATT). This study aims to help to provide evidence on whether ATT usage for Idiopathic Uveitis IGRA Positive would bring beneficial impact for the patients. This study will try to analyze the data from clinical improvements, Type 1 Interferon changes, and transcriptomics analysis from the patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Not willing to sign informed consent
  • Pregnant patient
  • Not coming to scheduled visit date
  • Uveitis caused by infectious origin
  • Media opacity caused by cataract and/ or corneal scar resulting in difficulty of posterior segment examination in both eyes
  • Chronic hypotony (IOP < 5 mm Hg for > 3 months) in both eyes
  • History of prior intraocular surgery in < 30 days, or arranged surgery within the next 6 months
  • Best spectacle-corrected visual acuity (BSCVA) of hand motions or worse in better eye
  • Any history of cancer excluding non-melanoma skin cancer
  • Abnormal Complete blood count (≤ 2,500 white blood cells and/or ≤ 75,000 platelets and/or ≤9 hemoglobin) within 4 weeks prior to enrollment^
  • Abnormal alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 2 times the upper limit of normal for the lab and/or creatinine ≥ 1.5 within 4 weeks prior to enrollment^
  • Patient with active infection of tuberculosis, HIV infection, syphilis, or hepatitis B or C
  • Note (^): Testing is conducted within 1-2 weeks prior to enrollment;
  • As many 10 subjects of the health volunteers are recruited for this study after giving consent. The health volunteers that will be recruited are the subject who met following criteria:
  • age: 18-50 years old (Man/Woman)
  • not having any health complaint or symptoms
  • not in any long term medication
  • body mass index: 18.5 - < 30
  • no history of allergy
  • willing to cooperate in this study
  • state of complete physical, mental, and social well being, and not merely the absence of disease or infirmity (WHO healthy definition)

研究组 & 干预措施

Observational cohort group

Subjects: idiopathic uveitis with IGRA positive.

Examinations:

  • Clinical improvement examinations at day 0, second week, week 8, month 3, month 6 and month 12.
  • Blood sampling at day 0, second week, month 6 for analysing type 1 IFN gene expression scoring using RT-qPCR methods.

干预措施: Fixed drug combination (FDC) of ATT and Oral steroid (Drug)

结局指标

主要结局

Proportion of clinical improvement

时间窗: 0, 14 days, 8 weeks, 3 months, 6 months, and 12 months

Clinical improvement of uveitis patients with IGRA positive after receiving complete Anti Tuberculosis Therapy is measured by using The Standardization of Uveitis Nomenclature (SUN) inflammation degree. Clinical improvement definition is decreasing of inflammation degree up to two degrees or becoming 0 degree. Meanwhile, clinical failure is defined by increasing of inflammation degree or decreasing of inflammation degree up to one degree/ not becoming 0 degree or unchanged degree of first to fourth degree.

The changes of type 1 interferon scoring in selected gene expression

时间窗: 0, 14 days, 6 months.

The score changes of type 1 interferon of uveitis patients with IGRA positive are determined by gene expression value of 10 varieties of type 1 interferon using Quantitative Reverse Transcriptase PCR (RT-qPCR) testing.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rina

Lecturer

Fakultas Kedokteran Universitas Indonesia

研究点 (1)

Loading locations...

相似试验